Novan Presents Preclinical Data from Inflammatory Skin Diseases Program
MORRISVILLE, N.C., April 27, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that data from two preclinical studies with SB414, a nitric oxide-releasing cream in development for the treatment of inflammatory …